Key Highlights

  • Abacus reported second-quarter 2026 Revenue of $73.0 million, up 30%, with adjusted Net Income of $27.1 million, or $0.28 a share, though GAAP net income fell to $6.6 million.
  • Its Business centers on longevity-based assets, chiefly life settlements, and it raised $544 million for its longevity funds in the first half of 2026.
  • The unusual Asset Class offers returns uncorrelated with markets, but brings actuarial, valuation, and interest-rate risks.
  • The company held $383.0 million of policy Assets on its Balance Sheet and generated Operating Cash Flow of $130.9 million for the year to date.

Abacus Global Management (NYSE:ABX) brings an unusual asset class to public markets because its core business is life settlements, buying life-insurance policies from the individuals who own them, paying a lump sum, taking over the premiums, and collecting the benefit when the insured person dies. It's a way of investing in longevity: the returns depend on actuarial outcomes rather than on the stock market.

Abacus is now building on that niche to become a broader manager of longevity-based assets, managing money for institutions as well as investing its own.

The Latest Results

For the second quarter of 2026, Abacus reported revenue of $73.0 million, up 30% from a year earlier, and $132.4 million for the first half, up about 32%. Adjusted net income rose 24% to $27.1 million, or $0.28 a diluted share. GAAP net income, however, fell 63% to $6.6 million, which the company attributed to strategic and personnel costs associated with acquisitions and growth. Operating cash flow surged to $130.9 million for the year to date.

How the Model Works, and Where It Is Going

Traditionally, a life-settlement company makes money on the spread between what it pays for a policy and what it ultimately collects, funding the purchases with its own capital, a balance-sheet-intensive approach. Abacus is shifting towards a more capital-light, asset-management model: raising funds from institutional investors and earning fees for managing longevity assets on their behalf. The $544 million raised for its longevity funds in the first half is evidence of that pivot.

The Opportunity

The opportunity is twofold: a differentiated asset class that offers returns uncorrelated with markets, and a transition towards higher-quality, fee-based asset management. Rapid revenue growth, strong operating cash flow, and high adjusted margins suggest the underlying Economics are healthy.

How Life Settlements Actually Work

Many people hold life-insurance policies they no longer need or can no longer afford, and if they simply stop paying, the policy lapses and they get little or nothing. A life settlement offers an alternative: a company like Abacus buys the policy for a lump sum larger than the insurer's surrender value, takes over paying the premiums, and becomes the beneficiary. Because the timing hinges on human longevity rather than on markets, the returns are largely independent of stock and bond prices.

The flip side is that the whole model rests on estimating life expectancy accurately across a portfolio of policies. Systematically underestimate how long people will live, and returns suffer because premiums must be paid for longer than assumed.

Risks

Life settlements depend on actuarial assumptions about how long insured individuals will live; if people live longer than expected, returns fall. Valuing a portfolio of policies is complex and relies on models and mortality data, so reported values carry estimation risk. The gap between GAAP and adjusted Earnings this quarter is a reminder to scrutinize how the company presents its results.

Scaling a Genuinely Uncorrelated Asset

The signals that matter are revenue and adjusted earnings growth; the pace of fund-raising and the build-out of the asset-management business; the relationship between GAAP and adjusted results; and the interest-rate environment. Abacus Global Management offers exposure to a genuinely unusual, market-uncorrelated asset class, and it's growing fast; the key questions are whether it can scale its asset-management ambitions and manage the actuarial and valuation risks that come with investing in longevity.